Table 3.
Test Type | Number of Tests | Sensitivity-Localized Disease1 | Sensitivity-Disseminated Disease1 | Specificity | Observed % Positive2 | Predicted % Positive3 | Predicted % Difference |
---|---|---|---|---|---|---|---|
Two-Tiered Whole Cell | 297,619 | 37.0% | 87.0% | 99.4% | 5.79 | 5.76 | 0.03 |
EIA/IFA standalone or first tier4 | 287,595 | 66.9% | 93.3% | 96.1% | 11.89 | 11.89 | 0.00 |
Observed percent positive values were derived by combining data from five large commercial laboratories for residents of four endemic states (CT, MD, MN, NY; see online supplement)
Predicted percent positive values were iteratively derived using data on the number of tests performed, Se and Sp of tests, an estimate for proportion of tests run from patients having localized/early disease, and an estimate for the true rate of infection (see online supplement)
Based on EIA/IFA standalone combined with first tier of two-tiered assays